General timeline: Week 12 at a new dose: Nausea most likely, especially after meals Week 34: Symptoms usually begin to ease noticeably Week 5+: Most users report little to no nausea at a stable dose Dose increase: The cycle may restart briefly at a lower intensity Common mistake: Stopping tirzepatide entirely after the first wave of nausea, before the body has had time to adjust
This once-weekly injectable medication, a dual GIP and GLP-1 receptor agonist, can be administered at any time of day, with or without meals, according to UK prescribing guidance
If youve been affected by this coverage change, send us your story today
As science evolves, DSIP may emerge as a new category of sleep aid one that helps the body recover naturally, rather than forcing it into sedation
Education and empowerment: Helping patients understand their diagnosis, symptoms, and treatment options so they can better navigate their care